RVMDPhase 2 Readout

RAS(ON) inhibitor expansion cohort update

Revolution Medicines | RMC-6236 | Pancreatic ductal adenocarcinoma

Catalyst details

Investor-tracked clinical update for RAS-mutant solid tumors.

Phase

Phase 2

Expected date

2026-07-10

Expected period

July 2026

Source type

manual

monthactive
Source URL

Notes

This record is structured for public-source tracking and manual analyst override. The database stores date confidence separately from exact dates so quarter, half-year, and estimated guidance can be handled without inventing precision.

Open company detail